Navigation Links
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Date:6/17/2008

chering Pharma AG, who has exclusive rights to Zevalin in all countries of the world except the U.S. CTI has now entered into an agreement with Bayer Schering Pharma to get access to this data. Under the terms of the agreement, CTI will make an initial payment to Bayer Schering Pharma with an additional payment upon FDA approval of a sBLA for Zevalin based on the FIT trial results. CTI also will pay Bayer royalties on net product sales up to a specified aggregate amount.

"We believe that gaining access to these important Zevalin trial data and regulatory documents will allow for the potential to expand the label in the U.S. to include consolidation of first-line therapy, as Bayer Schering Pharma did in Europe, and may give more patients access to the potential benefits of Zevalin," said James A. Bianco, M.D., President and CEO of Cell Therapeutics. "We are pleased with Bayer's willingness to support our efforts to potentially broaden U.S. patient access to this important therapeutic, and delighted to be working with such a talented group of dedicated healthcare professionals."

Cell Therapeutics has requested a meeting with the Food and Drug Administration (FDA) to discuss expanding the label for Zevalin in the U.S. to include consolidation following first-line treatment of follicular lymphoma based on the FIT trial data. If approved, this new indication has the potential to increase the market for Zevalin in the U.S.

About the Phase III First-line Indolent (FIT) Trial

The multinational, randomized phase III First-line Indolent Trial (FIT) evaluated the benefit and safety of a single infusion of Zevalin in patients with CD20-positive follicular lymphoma who had achieved a partial remission or a complete remission after receiving standard first-line chemotherapy regimens. The FIT trial results were presented in one oral and two poster presentations at the American Society of Hematology (ASH) conference in December 2007. The FIT trial demons
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
2. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
3. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
4. Chromos enters into loan and lending arrangements
5. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
6. CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order
7. STAAR Surgicals Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services
8. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
9. Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers
10. Finesse Solutions Expands by Opening Sales and Service Centers
11. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... MD (PRWEB) May 17, 2013 ... of ezColony version 4.1, a versatile refinement to ... premier software solution, improves its advanced methodical management ... facilities with ezColony 4.1. The network-based platform provides ... conduct effective research. While continuing to emphasize streamlined ...
(Date:5/16/2013)... 16, 2013 ISPE ... Myers, CAE, to the newly created position of ... role, Myers will be responsible for stimulating ISPE’s ... strategies, advancing the Society’s Member-led and staff-driven business ... to refine organizational, membership and product marketing. , ...
(Date:5/16/2013)... Kitware , a leading provider of ... II SBIR funding from the U.S. Department of ... high performance computing (HPC) simulation and computation framework. ... select only the toolkits and applications needed to ... tasks. , Manufacturers increasingly rely on simulation ...
(Date:5/16/2013)... 16, 2013 On average, developing a ... one billion dollars. Despite this investment, less than 10% ... high, is your clinical trial design optimally structured to ... outcomes? , Dr. Frederic Sax, Global Head of the ... use of data, information and technology in upfront clinical ...
Breaking Biology Technology:RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2
... available in German . , Carbon nanotubes ... promising candidates for optoelectronic components. However, so far it ... optic and electronic properties. A team of researchers headed ... Universitaet Muenchen and member of the Cluster of Excellence ...
... 7, 2011 Reportlinker.com announces that a ... its catalogue: http://www.reportlinker.com/p0368623/The-2011-Top-Ten-Worlds-Leading-Life-Science-Intermediates-Companies.html ... the competitive environment is widely recognized as ... the task crucial to business survival, growth ...
... Reportlinker.com announces that a new market research report ... Nanobiotechnologies- applications, markets and companies ... the creation and utilization of materials, devices, and ... nanometer-length scale (a nanometer is one billionth of ...
Cached Biology Technology:Ultra fast photodetectors out of carbon nanotubes 2Reportlinker Adds The 2011 Top Ten World's Leading Life Science Intermediates Companies 2Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 2Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 3
(Date:5/15/2013)... trial to date to examine the efficacy of PARP ... than breast and ovarian cancer, the oral drug olaparib ... prostate cancers. Results of the study, led by researchers ... of Pennsylvania and Sheba Medical Center in Tel Hashomer, ... Clinical Oncology,s annual meeting in Chicago in early June ...
(Date:5/15/2013)... N.Y. - Clam fossils from the middle Devonian era ... a better paleontological picture of the capacity of ecosystems ... according to research published today (May 15) in the ... examine species abundance the head counts of specimens ... The research shows that factors such as predation and ...
(Date:5/15/2013)... world-renowned filmmaker James Cameron has been named by Scripps ... recipient of the 2013 Nierenberg Prize for Science in ... his record-setting DEEPSEA CHALLENGE expedition and exploration of the ... on the UC San Diego campus. , In addition, ... and promise of the deep sea has been considerably ...
Breaking Biology News(10 mins):PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2Clam fossils divulge secrets of ecologic stability 2James Cameron to be publicly honored with Scripps Nierenberg Prize 2James Cameron to be publicly honored with Scripps Nierenberg Prize 3James Cameron to be publicly honored with Scripps Nierenberg Prize 4
... incandescent light bulb in the 19th century spurred on ... extending leisure time and bringing us to the point ... range of devices from mood lighting to audiovisual media ... vacuum cleaners to high-speed broadband connected computers in their ...
... Finland, has been the first in the world to ... in the treatment of osteoarthritis and rheumatoid arthritis. ... that allows the product to be sold in the ... since the mid-1990s, is the result of collaboration between ...
... This release is available in German . ... component of the Lily of the Valley scent known as Bourgeonal alters ... of the Valley phenomenon" also the title of a book about ... act as swimming olfactory cells which follow a "scent trail" laid by ...
Cached Biology News:Developing sustainable power 2Researchers develop world's first biodegradable joint implant 2The end of the 'Lily of the Valley phenomenon' in sperm research? 2The end of the 'Lily of the Valley phenomenon' in sperm research? 3
... a microprocessor controlled, high speed filter ... exceptionally smooth operation make the Lambda ... fluorescence microscopy, ratio imaging, spectrophotometry, visual ... and accurate aperture positioning. The Lambda ...
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
... enzyme that catalyzes the conversion,of starch ... maltotriose and,dextrins. The level of a-amylase ... are of clinical importance,1-3 while plant ... industry.4, The EnzChek Amylase Assay Kit ...
Rat monoclonal [20d5] to NKG2A + C+ E ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Mouse): CHO transfected cells expressing the B6 allele of NKG2A. Entrez Gen...
Biology Products: